

2022 Independent Medical Education Request for Proposals

Issue Date: September 16, 2022

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Independent Medical Education. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none"> ● U.S. based education provider ● Registered account in gFRS ● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none"> ● Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP have <u>5 weeks</u> to develop a proposal concept and submit an Executive Summary through funding.gene.com (gFRS).	October 21, 2022
Step 2	After 2 weeks, the Executive Summaries selected for further review will receive notice to submit a full grant application(s) through gFRS.	November 4, 2022
Step 3	Those providers who receive notification of selection for further review will have 2 weeks to submit full grant application(s) online through gFRS.	November 18, 2022
Step 4	Notifications of final decisions will be issued via gFRS.	December 9, 2022

Additional Considerations

Provider(s) who are awarded grants are encouraged to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Oncology</p> <p>Learning Audience: Oncologists</p> <p>Oncologic Surgeons</p> <p>Nurse Practitioners</p> <p>Physician's Assistants</p> <p>Support Available: Up to \$100,000</p> <p>Knowledge- and Competence-based National and Regional Education <i>(Understanding & addressing national or local gaps and emerging data)</i></p>	<p>Therapy options for patients with soft tissue sarcomas have historically been limited. Recently, important advances have been made in the application of immune checkpoint inhibitors for some soft tissue sarcomas, including alveolar soft part sarcomas (ASPS). Healthcare providers need education about new data for FDA-approved treatment options and current clinical trials for patients with soft tissue sarcomas.</p> <p>Due to the rarity of soft tissue sarcomas, there is wide variation in treatment approaches and low knowledge around best practices. With the addition of new options for patients with ASPS, healthcare providers need education about guideline recommendations, best practices, and multidisciplinary team coordination.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Tellez C, Leyfman Y, D'Angelo S, Wilky B, Dufresne A. Immunotherapy in Sarcoma. <i>Surgical Oncology Clinics of North America</i>. 2022;31(3):381-397 2. Chang X, Li Y, Xue X, Zhou H, Hou L. The current management of alveolar soft part sarcomas. <i>Medicine</i>. 2021;100(31)